Apellis Pharmaceuticals, Inc.
APLS
$17.97
$0.080.45%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -58.95M | 215.72M | -42.15M | -92.23M | -36.35M |
| Total Depreciation and Amortization | 327.00K | 339.00K | 446.00K | 446.00K | 447.00K |
| Total Amortization of Deferred Charges | 655.00K | 636.00K | 614.00K | 591.00K | 587.00K |
| Total Other Non-Cash Items | 21.25M | 28.19M | 27.20M | 27.37M | 26.31M |
| Change in Net Operating Assets | 22.55M | -136.41M | 18.34M | 10.40M | 28.37M |
| Cash from Operations | -14.18M | 108.47M | 4.45M | -53.41M | 19.36M |
| Capital Expenditure | -108.00K | -148.00K | -49.00K | -8.00K | -20.00K |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -108.00K | -148.00K | -49.00K | -8.00K | -20.00K |
| Total Debt Issued | -- | -- | -- | -- | 0.00 |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 1.26M | 797.00K | 6.56M | 281.00K | 1.64M |
| Repurchase of Common Stock | 0.00 | -4.00K | 0.00 | -7.00K | -15.00K |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -5.63M |
| Cash from Financing | 1.26M | 793.00K | 6.56M | 274.00K | -4.00M |
| Foreign Exchange rate Adjustments | 184.00K | 22.00K | 685.00K | 359.00K | -965.00K |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -12.84M | 109.14M | 11.64M | -52.79M | 14.38M |